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INTRODUCTION 46
Brucellosis is a zoonotic disease caused by the gram-negative, facultative coccobacilli 47 bacteria of the genus, Brucella. Brucella spp reside intracellularly within the host 48 organism, preferring macrophages and macrophage-related cells. However, they also 49 can persist extracellularly or outside the host. Symptoms of the disease are variable, 50
including undulant fever, osteoarticular, genitourinary, and neurological complications. 51
Within the host, Brucella have demonstrated the ability either to hide from or misdirect 52 the immune response leading to chronic disease and complicating vaccine development 53
(1). Although cytotoxic T lymphocytes (CTL) are a potentially major contributor to the 54 control of brucellosis (2-4), the actual role of MHC class I-restricted CTL is unclear. One 55 study demonstrated that the absence of perforin did not affect the level of infection (5, 56 6). On the other hand, in the study by Oliveira et al. 2m-/-mice were impaired in 57 containment of Brucella infection(7), and Murphy et al. showed that CD8 T cell depletion 58 exacerbated disease (8) . Brucella have the ability to sabotage adaptive immune 59 response, through undefined suppressive or regulatory means leading to the 60 appearance of apparently exhausted CD8 T cells (3). The events producing exhaustion, 61 as well as the nature of this state during chronic Brucella infection await better definition 62 but nevertheless suggest that CTL could be key in limiting infection if not suppressed. In 63 other model systems of CD8 exhaustion, notably lymphocytic choriomeningitis virus 64 (LCMV), the study of T cell responses has benefited tremendously from the availability 65 of specific research tools such as T cell receptor (TCR) transgenics. In comparison, 66
Brucella research has been relatively hindered by the inability to identify antigen specific 67 T cells. Although peptide epitopes have been published, there are no functional 68 tetramers. To address this deficit, we sought to engineer Brucella to express a defined 69 antigen that the infected antigen presenting cell (APC) would present in the context of 70 MHC class I (MHC I) to more readily characterize the immune response to Brucella 71 infection using a mouse model. 72
73
Due to its long history in immunological research, OVA is one of the best characterized 74 model antigens, with epitopes that have been mapped for several mouse strains. 75
Transgenic mice expressing the variable region of the TCR specific to the OVA peptide 76 SIINFEKL (9) are referred to as OT-1. Every CD8+ T cell expresses this TCR transgene 77 (10). The combination of OT-1-TCR-transgenic T cells and OVA-derived peptide 78 SIINFEKL in the context of H2K b is the most widely examined TCR-pMHC (peptide-79 MHC) complex (10, 11). Because of these readily available research tools, OVA has 80 been a reference protein used to study CD8 T cell responses in other intracellular 81 infections. Previous research has shown that intracellular bacteria such as Listeria 82 5 monocytogenes or Mycobacterium bovis (BCG) expressing the OVA antigen induce 83 strong antigen-specific primary and memory CD8 T cell responses (12) (13) (14) (15) . 84
85
In this study, we engineered and characterized OVA-expressing Brucella with the intent 86 of studying primary and secondary CD8 T cell responses in acute and chronic 87 brucellosis using the mouse model. Unexpectedly, we found the research tools used to 88 analyze OVA antigen-specifically the cloned OT-1 TCR that recognizes SIINFEKL 89 peptide presented by H2K b -reacted to native Brucella infection as well. We therefore 90 hypothesized that the Brucella proteome contains sequences similar to, or mimicking, 91 the OVA SIINFEKL peptide. These results suggest the OT-1 TCR transgenic mice may 92 be used to study native Brucella infections and further raises questions about the nature 93 of cross presentation and molecular mimicry. 94
95

MATERIALS AND METHODS
96
Mice. C57BL/6 (Harlan) and C57BL/6-Tg(TcraTcrb)100Mjb/J (Jackson) were housed 97 and cared for in AAALAC certified facilities of the University of Wisconsin School of 98 Veterinary Medicine. Care, handling and experimental procedures were approved by 99 was immediately added to the cells followed by overnight shaking in an incubator at 139 37C. The next day, 200 l of cells were plated on BHI agar plates containing 50 mg/L 140 kanamycin. Plates were cultured for 5-7 days at 37C. Clones were then selected and 141 cultured in 96-well plates as a bacterial library and clones from the library were then 142 propagated for rescue cloning of the transposon insertion site. Rescue cfp #4). Positive control were cells pulsed with OVA peptide (SIINFEKL) as described 205 above. Targets, effectors, and controls were plated, incubated, and assayed as 206 described for immune effectors CTL assay above following the manufacturer's 207 (Promega) recommended protocol and calculations for percent specific cytotoxicity. 208
209
IFN-γ Enzyme Linked Immunosorbent Assay (ELISA). Effector cells were prepared 210
by immunizing mice (C57/BL6) as described for the CTL experimental group above 211 except that an additional group was immunized with OVA peptide (SIINFEKL) at 50 g 212 in 0.2 ml Sigma Adjuvant System (Sigma) i.p. following the manufacturer's protocol. 213
Peptide immunizations were boosted after 2 weeks and one week later, splenocytes 214 were harvested. Splenocytes from each animal were then stimulated in culture with 1 215 g/ml of SIINFEKL peptide and incubated for 48 h at 37 °C. Cultured supernatants were 216 harvested, and IFN-γ amounts were determined using the ELISA Ready-Set-Go! 217 System (Affymatrix; eBioscience) following the manufacturer's protocol. (ONPG assay). For X-Gal staining, cells were fixed with 4% PFA for 10 min, then 229 washed 3X in PBS, and overlaid with a solution of 1 mg X-Gal/ml, 5 mM potassium 230 ferrocyanide, 5 mM potassium ferricyanide, and 2 mM MgCl 2 . After an overnight 231 incubation at 37°C, plates were examined microscopically for the presence of blue (lacZ 232 expressing) cells. For ONPG staining, we used a SensoLyte ONPG -Galactosidase 233
Assay kit (AnaSpec, Inc) following the manufacturer's recommended protocol except 234 that the incubation at 37°C was overnight. Absorbance reading was at 405 nm. 235 236
Prediction of near neighbors 237
Structural diagrams of binding of SIINFEKL in the H2K b murine MHC I molecule (3P9L) 238 (19) illustrate that this octomer is bound with its C terminal leucine located in the P9 239 pocket position and the N terminal serine in the P2 pocket position. This results in a 240 pentamer peptide exposed to the T cell receptors (T cell exposed motif or TCEM) (20). 241
Amino acids N, E and K protrude particularly prominently from the MHC groove in 242 positions P5, P7, and P8. By replacing amino acids with those of similar 243 physicochemical characteristics in T cell exposed positions P4-P8, 31 peptides were 244
identified which a T cell receptor would likely tolerate and bind as an alternate "near 245
neighbor" of SIINFEKL. The amino acid substitutions in the exposed positions included were noted, and the predicted binding to murine MHC I alleles was determined in the 251 context of the native Brucella protein using previously described methods (21), and the 252 probability of cathepsin cleavage at the C terminus of that peptide determined (22, 23). and rescue cloning performed to determine the transposon insertion site ( Table 1) . 275
Western blotting of chosen clones using anti-OVA or anti-GFP specific antibodies 276 determined protein expression (Figure 2) . Viability of transformed clones were 277 compared to parental Brucella by growth in broth as well as intracellular growth in vitro 278 and in vivo measuring CFU from infected BMDM in culture or CFU from splenocytes of 279 infected mice (Figure 3) . Clones with comparable growth to wild type (clones #3 and 280 #4) with insertion in BMEI 1025 and BMEII 0058 respectively (Table 1) with OVA-expressing Brucella and analyzed by fluorescence microscopy (Figure 4) . 290
Results indicate that SIINFEKL peptide-MHC I complexes could be directly visualized 291 on the Brucella-OVA infected macrophages. 292 293 Antigen from wild type Brucella mediates OT-1 (OVA-specific) T cell activation 294 and generates effectors capable of recognizing SIINFEKL bound MHC I. As these 295 results indicated that the OVA-CFP fusion protein was processed in infected cells, and 296 that SIINFEKL was presented by H2K b , we proceeded to T cell immune response 297 studies. Unexpectedly, CD8+ effector T cells from mice immunized with parental and 298 OVA expressing Brucella both reacted to SIINFEKL-pulsed targets (Figure 5A) . 299
Indeed, effectors from control B. melitensis immunized animals lysed OVA peptide 300 pulsed targets at a level not significantly different than the OVA-expressing Brucella. 301
These data indicate that B. melitensis immune cells can recognize OVA peptide-MHC I. 302
Similar results were observed in separate experiments examining IFN- cytokine 303 production. B. melitensis immunized effectors produced IFN- in response to SIINFEKL 304 peptide at levels not significantly different from the B. melitensis OVA immunized 305 effectors (Figure 6A) . As expected, IFN- expression from Brucella immunized animals 306 was significantly less than from OVA-peptide immunized animals. To confirm that the 307 immunized cell response to SIINFEKL was specific, a separate immunization 308 experiment was performed using SIINFEKL and a scrambled peptide to pulse the cells 309 ( Figure 6B) . Production of IFN- by splenocytes from Brucella-immunized mice was 310 also significantly higher in the presence of SIINFEKL peptide as compared to a 311 scrambled control peptide. 312
313
To affirm these unexpected results, we altered our CTL assay approach by utilizing the 314 well characterized SIINFEKL-specific T cell receptor expressing OT-1 CD8+ T cells from 315 TCR transgenic mice. This time the effectors (OT-1) were OVA-peptide specific and the 316 targets were Brucella infected. Targets pulsed with SIINFEKL served as a positive 317 control. Again, non-OVA expressing Brucella infected targets were lysed by OT-1 318 effectors at similar levels to OVA expressing Brucella (Figure 5B) . As expected, OVA-319 peptide pulsed targets lysed at significantly higher levels. 320
321
One possible explanation of the results presented above could be that Brucella infection 322 non-specifically activates T cells because of its effect on antigen presenting cells, or that 323 we may be observing cross-reactivity of the OT-1 receptor to mouse peptides. Brucella 324 infection induces ER stress and IFN production, either of which could potentially 325 modulate antigen presentation (1, 18, 26). The SIINFEKL specific responses by 326
Brucella-immune cells were significantly greater than un-pulsed or scrambled controls 327 (Figure 6B) , arguing against non-specific host stimulation of T cells as the sole 328 explanation. However, to address this theory more directly, we treated the antigen 329 presenting cells with infection-associate factors that could potentially alter MHC I- Brucella. We performed a search of the B. melitensis proteome for the SIINFEKL 348 sequence. The proteome of B. melitensis does not contain a peptide identical to 349 SIINFEKL. However, 38 peptides were found that comprise a P4-P8 T cell exposed 350 motif matching one of the peptides having near neighbor physicochemical 351
characteristics. Supplemental Table S1 shows these peptides, the Brucella proteins of 352 origin and the predicted binding affinity to murine MHC I alleles H2K b and H2D b of the 353 nonamer peptides that contain these motifs. For those peptides having the highest 354 predicted binding affinity to H2K b or H2D b , the probability of C terminal cathepsin 355 excision was examined. Interestingly, for peptides which were predicted to have a high 356 probability of C terminal cleavage by either cathepsin S or L to permit MHC I binding, 357 cleavage probability was highest at the position P10, i.e. yielding a decamer peptide. 358 This is consistent with prior observations that indicate that a decamer may be more 359 likely to be initially excised than a nonamer (23). This selection process yielded a 360 ranking of peptides for further study, where four were selected for testing. In making this 361 selection we also considered proteins that had clearly detectable expression observed 362 during our previous proteomics and RNAseq studies of infected cells (18). For controls 363 we selected a peptide comprising a near neighbor motif that was predicted to have low 364 affinity for H2K b or H2D b , and a random nonamer peptide. Table 2 describes the 365 peptides used in these studies. scanning of the lacZ stained cells revealed that all the peptides tested in Table 2 , 381 except the random sequence, had some level of staining above background (no peptide 382 added). In fact, three of the peptides (KSIINAERL, PQKINIDRT, and KNKINLDKL) 383 were observed to have staining similar to SIINFEKL (Figure 8) . We then repeated our 384 assays using peptide dilutions to assess avidity of the pulsed peptide-MHC I and TCR 385 interaction. The ONPG assays (Figure 9 ) verified our lacZ results that three of the 386 experimental peptides (KSIINAERL, PQKINIDRT, and KNKINLDKL) had high levels of 387 TCR (NFAT) activation. ONPG assays also revealed different avidities for the peptides. 388 Figure 9B shows that whereas SIINFEKL avidity did not change much at all dilutions 389 tested, the Brucella peptide avidity decreased with dilution. Notably, the native Brucella 390 KSIINAERKL peptide did not differ significantly from the SIINFEKL peptide until To determine if infection with the parental B. melitensis 16M generated immune 394 responses to these OVA-TCR cross reactive peptides in vivo, splenocytes from mice 395 immunized with either B. mel or B. mel-OVA were assayed for IFN- production after 396 stimulation with peptide (Figure 10) . Immune cells did indeed respond to the panel of 397 cross-reactive peptides with greater cytokine production than to scrambled peptide, 398
suggesting these epitopes may be generated in vivo. 399
400
Finally, we determined if these native Brucella peptides could activate OVA-specific 401 TCR using the OT-1 mouse system. Splenocytes from these mice were pulsed with the 402 various peptides and IFN- expression was measured by ELISA. Results shown in 403 OT-1 TCR is cross reactive to peptides of the Brucella proteome. Peptide immunization 405 of the OT-1 mice was not attempted due to an anticipated hyper-immune response (9, 406 10). Indeed, when we tried infecting these mice with Brucella and the Brucella-OVA 407 mutants, the mice died within six days (data not shown). 408
409
DISCUSSION
410
The immune response to Brucella melitensis is complex, as evidenced by the fact that 411 there is currently no known effective brucellosis vaccine available. Our research goal 412 was to engineer Brucella to express immunogenic OVA as a tool to follow antigen-413 20 specific effector and memory immune responses to Brucella infection in vivo, using the 414 mouse model. Adopting this approach, we could employ SIINFEKL-MHC tetramers and 415 T cells from TCR transgenic mice. This goal was nominally fulfilled. However, the 416 surprising result was that native Brucella also stimulated "OVA-specific" TCR of OT-1 417 mice. Employing a panel of near-neighbor Brucella peptides, cross-reactivity of the 418 OVA-TCR was evident, although to a lesser extent than the OVA SIINFEKL that was 419 originally used in clonal selection of the TCR (10, 11, 31 ). Despite the lower avidity, as 420 indicated by the B3Z assays, Brucella peptides from infections were sufficiently 421 immunogenic to trigger both robust cytokine and CTL responses via the OVA TCR. 422
These results suggest that the OT-1 TCR transgenic T cells may be used to probe 423
native Brucella immune responses as well as responses to the Brucella-OVA. 424
425
A search of the Brucella melitensis proteome revealed several proteins containing T cell 426 exposed pentamer motif sequences with physicochemical characteristics similar to 427 SIINFEKL. Such "near neighbor" pentamers were also identified in many other bacteria. 428
This included proteomes of Listeria monocytogenes, Salmonella enterica, and 429
Mycobacteria bovis BCG. Listeria, Salmonella, and BCG have all been engineered to 430 express OVA similar to the approach shown here with Brucella (13, 32, 33). However, 431 no cross-reactivity of native bacterial peptides to OVA specific TCR was reported. This 432 may be because the flanking amino acid context precluded binding and presentation in 433 these bacteria, or that this phenomenon has been observed with other bacteria but not 434 reported (34). The occurrence of near neighbor pentamers in the gastrointestinal 435 microbiome organisms suggests that prior exposure to such peptides is difficult to avoid. 436 species including B. abortus, B. suis, B. neotomae,  437 and B. ovis showed these pentamer motif sequences to be conserved. One limitation of 438 this study is that it would not be feasible to delete all genes coding the SIINFEKL near 439 neighbors to definitively confirm the connection between production of SIINFEKL cross 440 reactive peptides and recognition of infected cells by OT-1 T cells. Additionally, the 441 proteins containing the peptides listed in Table 2 used in these studies may be essential 442 for survival. In searching the literature describing Brucella mutants, we could not find 443 engineered mutants of these proteins (35, 36) (37, 38), possibly because they did not 444 survive the mutation process or were severely attenuated. 445
Sequence scans of other Brucella
446
An intriguing alternative to our explanation could be that Brucella infection alters 447 presentation of the host proteome. Indeed, our previous studies have found Brucella 448 induces the host Unfolded Protein Response (39, 40) and this ER stress could 449 theoretically alter host or self-antigen presentation. Further, immune activation during 450
Brucella infection results in IFN- production, which is known to up-regulate MHC I 451 expression and self-antigen presentation. Searching the C57/BL6 mouse proteome 452 revealed no SIINFEKL peptide sequence. However, applying our near neighbor 453 algorithm did reveal 22 instances of ~~~INFEK~ sequence that would potentially be 454 exposed to the T cell. Nevertheless, the predicted binding affinity to H2K b or H2D b was 455 low compared to the Brucella peptides used in this study (data not shown). Testing this 456 theory using UPR inducer/inhibitors and a cytokine APC activator did not enhance 457 stimulation of the OVA-specific TCR expressing B3Z T cells. These results suggest the 458 host (mouse) does not present an OVA-like peptide due to ER stress or APC activation 459 by IFN-. 460
461
Activation of the T cell through the T cell receptor by peptide-MHC I had been thought to 462 be peptide specific; however, our results, along with others (41-45) have shown that T 463 cells can be triggered by peptides with even minimal obvious homology to the primary 464 immunogenic peptide, or amino acid substitutions with similar charge and size. The 465 TCR recognizes an immunogenic complex consisting of peptide bound to MHC I with 466 peptides of 8-11 amino acids in length (46). Of those amino acids, only five are exposed 467 to the TCR (20, 47). Given the genetic combinatorial rearrangement possibilities, an 468 estimated 10 15 unique TCRs could be generated in the mouse (43). However, studies 469 have shown there are actually <10 8 distinct TCR clones in the human naïve T cell pool 470 (48), and likely a similar number in mice. Since 20 9 foreign peptide nonamers can 471 theoretically be generated, it would be mathematically impossible for the T cell pool to 472 recognize all foreign peptides if the TCRs were monospecific (44). Therefore, the TCR 473 must be degenerate and cross-reactive to near-neighbor motifs as demonstrated here. 474
In fact, a TCR is estimated to react productively with 1 x 10 6 different MHC-peptides 475 epitopes (49). T cell cross-reactivity has also been documented using the OT-1 476 transgenic mice model we used in this study (10). Nevertheless, the degeneracy of the 477 TCR correlated with differences in avidity to the peptide-MHC I complexes as others 478 have reported (50). Our studies confirmed that higher concentrations of a degenerate 479 peptide were needed to activate the "SIINFEKL-specific" TCR to the same level 480 activation as SIINFEKL itself. Noteworthy is our observation that antibody to H2K b 481 
